ArticleNature biotechnology2016
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.
Article in Nature biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 105 citations in OpenAlex.
- Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review.Frontiers in pharmacology · 2026Review
- Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1.Journal of neuro-oncology · 2025Article
- Information-Distilled Generative Label-Free Morphological Profiling Encodes Cellular Heterogeneity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Leukemia circulation kinetics revealed through blood exchange method.Communications biology · 2024Article
- Article
- Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.JCO precision oncology · 2024Article
- Review
- PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models.Cell reports. Medicine · 2023Article
- Tailoring the Sensitivity of Microcantilevers To Monitor the Mass of Single Adherent Living Cells.Nano letters · 2023Article
- A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements.Communications biology · 2022Article
- Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer.Communications biology · 2022Article
- Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?International journal of molecular sciences · 2022Review
- High-resolution mass measurements of single budding yeast reveal linear growth segments.Nature communications · 2022Article
- Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics.Cancer discovery · 2022Review
- Density fluctuations, homeostasis, and reproduction effects in bacteria.Communications biology · 2022Article
- Characterization and identification of cell death dynamics by quantitative phase imaging.Journal of biomedical optics · 2022Article
- Mechanical phenotyping reveals unique biomechanical responses in retinoic acid-resistant acute promyelocytic leukemia.iScience · 2022Article
- Immunotherapeutic Approaches for Glioblastoma Treatment.Biomedicines · 2022Review
- Application of Microfluidics in Detection of Circulating Tumor Cells.Frontiers in bioengineering and biotechnology · 2022Review
- Microfluidics for Cancer Biomarker Discovery, Research, and Clinical Application.Advances in experimental medicine and biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 3 countries.
Funding
Abstract
Assays that can determine the response of tumor cells to cancer therapeutics could greatly aid the selection of drug regimens for individual patients. However, the utility of current functional assays is limited, and predictive genetic biomarkers are available for only a small fraction of cancer therapies. We found that the single-cell mass accumulation rate (MAR), profiled over many hours with a suspended microchannel resonator, accurately defined the drug sensitivity or resistance of glioblastoma and B-cell acute lymphocytic leukemia cells. MAR revealed heterogeneity in drug sensitivity not only between different tumors, but also within individual tumors and tumor-derived cell lines. MAR measurement predicted drug response using samples as small as 25 μl of peripheral blood while maintaining cell viability and compatibility with downstream characterization. MAR measurement is a promising approach for directly assaying single-cell therapeutic responses and for identifying cellular subpopulations with phenotypic resistance in heterogeneous tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.